Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
IPO Year: 2016
Exchange: NASDAQ
Website: pulsebiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2022 | $43.00 → $20.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $46.00 → $43.00 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $28.00 | Overweight | Stephens & Co. |
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
European feasibility study demonstrates using nano-PFA in benign thyroid nodules reduces nodule volume by greater than 50% and provides symptomatic relief within the first month of treatment Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate that nano-PFA pulses effectively
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in
Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic callers or 1-201-389-0912 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medi
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation Completed the first procedure with the Percutaneous Electrode System in the United States following U.S. FDA 510(k) clearance for the ablation of soft tissue and subsequently completed cases at five sites across the United States. The Company expects to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commerc
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech
Company's proprietary system used in study for patients with atrial fibrillation Cardiac Surgery System enrolled in the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP)* Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation. Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company's Cardiac Surgery System to successfu
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced plans to participate in two upcoming investor conferences. 9th Annual Needham MedTech & Diagnostics 1x1 Conference, virtual participation. Management will host 1x1 meetings on Tuesday, August 13, 2024. There will be no formal presentation. Canaccord Genuity Annual Growth Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, August 14, 2024, at 8:00am ET. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. Abo
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medi
Provides expanded access to FDA and prioritized review of submission Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has received the Breakthrough Device Designation from the U.S. FDA for the Company's Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF). Pulse Biosciences' Cardiac Surgery System with Surgical Clamp is designed to produce durable, continuous transmural ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation. The bipolar clamp utili
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
NT 10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
424B5 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
4 - Pulse Biosciences, Inc. (0001625101) (Issuer)
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic callers or 1-201-389-0912 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medi
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation Completed the first procedure with the Percutaneous Electrode System in the United States following U.S. FDA 510(k) clearance for the ablation of soft tissue and subsequently completed cases at five sites across the United States. The Company expects to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commerc
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medi
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent Business Highlights CellFX nsPFA Percutaneous Electrode March 2024, received FDA 510(k) clearance for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures. CellFX nsPFA Cardiac Clamp Remain in the 510(k) process while continuing productive dialogue with FDA regarding the go-forward regulatory path. FDA has requested clinical data in support of the regulatory filing and discussions regardi
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights CellFX nsPFA Percutaneous Electrode (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system) Received U.S. FDA 510(k) clearance for use in non-cardiac soft tissue ablation. Completed enrollment in the 30-patient first-in-human clinical trial on the treatment of benign thyroid nodules and principal investigator Dr. Stefano Spiezia presented the groundbreakin
Pulse Biosciences, Inc. (NASDAQ:PLSE, "the Company"))), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307706065/en/CellFX nsPFA Percutaneous Electrode System (Source: Pulse Biosciences, Inc.) "The FDA clearance of our Percutaneous Electrode System is the initial major milestone for Pulse Biosciences in
Pulse Biosciences will host Third Quarter 2023 Financial Results conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023 Pulse Biosciences, Inc. (NASDAQ:PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for the cardiac surgical clamp between December and end of first quarter 2024 and to commence
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously
Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00
Maxim Group initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $40.00
Maxim Group initiated coverage of Pulse Biosciences with a rating of Buy
HC Wainwright reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $46.00 from $40.00 previously
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $40.00 from $16.00 previously
Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech
Appoints proven atrial fibrillation medical technology leader Burke T. Barrett as President and Chief Executive Officer Former President and Chief Executive Officer Kevin Danahy appointed as Chief Commercial Officer Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ("Pulse"), today announced enhancements to its executive leadership team to support its next pivotal phase of growth. Proven atrial fibrillation medical technology leader Burke T. Barrett has been appointed President and Chief Executive Officer effective immediately. Concurrently, the Company announced the appointment of Kevin
Renowned Cardiothoracic Surgeon to Join Experienced Medical Device Technology Leadership Team to Bring nsPFA to Cardiac Surgery Pulse Biosciences, Inc. (NASDAQ:PLSE, "the Company"))), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the appointment of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery. "After working with the Pulse Biosciences' team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear to me that nsPFA has the potential to not only replace all other energy modalities in cardiac ablati
Leading Cardiothoracic Surgeon Joins Leadership Team as the Company Leverages its Proprietary nsPFA™ Technology for the Treatment of Atrial Fibrillation Pulse Biosciences, Inc. (NASDAQ:PLSE), Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced the appointment of Gansevoort "Gan" Dunnington, M.D. as its Chief Medical Officer. "On behalf of the Company, I am thrilled to welcome Dr. Dunnington to the Pulse Biosciences team," said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. "Dr. Dunnington brings a wealth of knowledge, expertise, an
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer. "As an industry veteran, Kevin has a proven track record of building exceptional commercial teams and implementing strategies to drive market penetration and significant growth with new medical technologies across a variety of medical disciplines," said Darrin Uecker, President and CEO of Pulse Biosciences. "His broad experience selling complex novel platform technologies makes Kevin uniquely qualified to take on the Chief Com
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuono's appointment, Kenneth Clark has resigned from the Board of Directors. "We are delighted and honored to welcome Laureen to the Pulse Biosciences Board," said Robert Duggan, Chairman of the Pulse Biosciences Board of Directors. "Laureen is an accomplished executive with a track record of driving growth and creating shareholder value through operational, financial and strategic execution for multiple life sciences, medical tech
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors. "As a Board member and medical device industry veteran with a track record of successfully bringing new technologies and products to market across a variety of medical specialties, Mitch's insights have benefitted Pulse Biosciences for over five years," said Darrin Uecker, President and CEO of Pulse
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™) technology, announced today that on December 31, 2020, it delivered a notice of redemption to redeem all of its outstanding warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), issued on June 16, 2020 in connection with the Company’s rights offering pursuant to its Registration Statement on Form S-3, as amended (File No. 333-237577), and that remain unexercised at 6:30 p.m., Eastern time, on February 5, 2021 (the “Redempt
SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13G/A - Pulse Biosciences, Inc. (0001625101) (Subject)
The Russell 2000 index of small caps, tracked by the iShares Russell 2000 ETF (NYSE:IWM), recorded its best weekly performance since October 2023, surging over 6% and reaching its highest level since January 2022. The rally was largely driven by Thursday’s session, where the Russell 2000 posted a remarkable 3.6% daily gain. This spike followed lower-than-expected June inflation data, which fueled speculation of potential interest rate cuts. However, Quincy Krosby, chief global strategist for LPL Financial, advises caution, suggesting that Russell 2000’s rate cut message may be “clouded by Fed’s concerns over labor market.” Krosby thinks a weaker labor market would still hurt the eco
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its second-quarter core sales guidance. The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45). Corning shares jumped 9.4% to $42.05 on Monday. Here are some other big stocks recording gains in today’s session. Morphic Holding, Inc. (NASDA
Based on a preliminary tabulation by Broadridge Corporate Issuer Solutions, Inc. (the "Subscription Agent"), as of the Expiration Date, the Company received basic subscriptions and over-subscriptions in excess of $83 million, equal to approximately 138% of the $60 million limit in the rights offering, and subscriptions from over 800 accounts, including those of the Company's Executive Chairman, Robert Duggan. Available Units will therefore be allocated proportionately among those rights holders who exercised their over-subscription right based on the number of Units each rights holder subscribed for under its basic subscription rights, in accordance with the procedures described in the prosp
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the "Units," and each, a "Unit") at the Initial Price (as defined below). The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m., Eastern Time, on June 26, 2024 (the "Expiration Date").
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million. Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million. Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million. Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards b
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million. Bionomics (NASDAQ:BNOX) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million. Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million. Xtant Medical Hldgs (AMEX:XTNT) stock moved upwards by 20.97% to $0.9. The market value of their outstandi